|
|
|
|
|
CUSIP No. 743815102 |
|
13D/A |
|
Page
8
of 10 |
Explanatory Note: This Amendment No. 22 (this Amendment) to the Schedule 13D
(the Initial 13D) relating to the common stock, par value $0.001 per share (Common Stock) of ModivCare Inc. (the Issuer), filed by the Reporting Persons with the Securities and Exchange
Commission (the SEC) on July 30, 2012 and as amended and supplemented by Amendment No. 1 to the Initial 13D filed on August 20, 2012, Amendment No. 2 to the Initial 13D filed on September 13, 2012,
Amendment No. 3 to the Initial 13D filed on November 28, 2012, Amendment No. 4 to the Initial 13D filed on August 15, 2013, Amendment No. 5 to the Initial 13D filed on October 28, 2014, Amendment No. 6 to the
Initial 13D filed on February 23, 2015, Amendment No. 7 to the Initial 13D filed on March 16, 2015, Amendment No. 8 to the Initial 13D filed on March 17, 2017, Amendment No. 9 to the Initial 13D filed on
December 13, 2017, Amendment No. 10 to the Initial 13D filed on May 10, 2018, Amendment No. 11 to the Initial 13D filed on June 1, 2018, Amendment No. 12 to the Initial 13D filed on June 7, 2018, Amendment
No. 13 to the Initial 13D filed on November 14, 2019, Amendment No. 14 to the Initial 13D filed on June 12, 2020, and Amendment No. 15 to the Initial 13D filed on November 12, 2020, Amendment No. 16 to the Initial
13D filed on September 9, 2021, Amendment No. 17 to the Initial 13D filed on May 10, 2023, Amendment No. 18 to the Initial 13D filed on August 10, 2023, Amendment No. 19 to the Initial 13D filed on August 11, 2023,
Amendment No. 20 to the Initial 13D filed on September 11, 2023, and Amendment No. 21 to the Initial 13D filed on September 13, 2023, amends and supplements certain of the items set forth therein.
As used in this Amendment, the term Reporting Persons collectively refers to:
|
|
|
Coliseum Capital Management, LLC, a Delaware limited liability company (CCM);
|
|
|
|
Coliseum Capital, LLC, a Delaware limited liability company (CC); |
|
|
|
Coliseum Capital Partners, L.P., a Delaware limited partnership (CCP); |
|
|
|
Coliseum Capital Partners II, L.P., a Delaware limited partnership (CCP2);
|
|
|
|
Adam Gray (Gray); and |
|
|
|
Christopher Shackelton, a director of the Issuer (Shackelton). |
Item 3. Source and Amount of Funds or Other Consideration.
Item 3 is hereby amended and supplemented as follows:
Since the
filing of Amendment No. 21 to the Initial 13D, the source and amount of funds used in purchasing the shares of Common Stock by CCP and a separate account investment advisory client of CCM (the Separate Account) were as
follows:
|
|
|
|
|
|
|
Purchaser |
|
Source of Funds |
|
Amount |
|
CCP |
|
Working Capital |
|
$ |
8,636,315.70 |
|
Separate Account |
|
Working Capital |
|
$ |
2,181,157.32 |
|
Item 5. Interest in Securities of the Issuer.
Item 5 is hereby amended and supplemented as follows:
(a)-(b) |
The information relating to the beneficial ownership of Common Stock by each of the Reporting Persons set forth
in Rows 7 through 13 of the cover pages hereto is incorporated herein by reference. The percentages set forth in Row 13 for all cover pages filed herewith are calculated based upon 14,181,255 shares of Common Stock outstanding as of July 28,
2023, as reported in the Issuers Quarterly Report on Form 10-Q, as filed with the SEC on August 4, 2023. |